Themis Medicare Ltd
NSE:THEMISMED
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IN |
|
Themis Medicare Ltd
NSE:THEMISMED
|
7.7B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
566.4B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
287.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
297.4B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
229.6B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
98.9B EUR |
Loading...
|
Market Distribution
| Min | -153 833.3% |
| 30th Percentile | 2.7% |
| Median | 7.3% |
| 70th Percentile | 13.2% |
| Max | 9 977% |
Other Profitability Ratios
Themis Medicare Ltd
Glance View
Themis Medicare Ltd. is a holding company, which engages in the manufacture of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2007-04-02. The firm is focused on the formulation and active pharmaceutical ingredients (API) activity. Its product category includes star products, differential products, and APIs. Its star products include OD-LM (Levocetrizine 5 mg + Montelukast 10 mg), Medzol (Midazolam hydrochloride 1 ml, 5ml and 10 ml), Cisatra (Cisatracurium 2 mg/ml), and Aquadol (Diclofenac sodium 75mg/ml). Its differential products include Enterofizz-EL (Bacillus clausii + Electrolytes) and Etojet (Etoricoxib 90mg/ml). Its APIs products include Simvastatin, Ketamine Hcl, and Isosorbide Di Methyl Ether (THEMISOL).The Company’s manufacturing locations in India are situated at Vapi, Haridwar and Hyderabad. The firm markets in over 44 countries. Its subsidiaries include Artemis Biotech Limited, Themis Lifestyle Private Limited, and Carpo Medical Limited (UK).
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Themis Medicare Ltd is -6%, which is below its 3-year median of 9.7%.
Over the last 3 years, Themis Medicare Ltd’s Operating Margin has decreased from 17.7% to -6%. During this period, it reached a low of -6% on Oct 30, 2025 and a high of 17.7% on Aug 30, 2022.
